Vitamin D’s promise for pancreatic cancer
A clinical trial suggests that a synthetic form of vitamin D, paricalcitol, can improve survival rates in pancreatic cancer patients when combined with chemotherapy. The supplement helps reduce protective fibrous barriers around tumors, allowing the immune system to attack cancer cells more effectively.
Why it matters
Pancreatic cancer is notoriously difficult to treat, and this novel approach could significantly improve patient outcomes and therapeutic efficacy.
Patients receiving a type of vitamin D lived longer after chemotherapy for pancreatic cancer in a small clinical trial run by researchers from the Dana-Farber Cancer Institute in California, United States.
The report is based on scientific findings published in a peer-reviewed journal and maintains a neutral, informative tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in